REPLIMUNE GROUP, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.56 USD | +2.18% |
|
+1.56% | -22.66% |
| 04-08 | Replimune Group Provides Interim Results for Skin Cancer Therapy | MT |
| 03-26 | Replimune Group, Inc. Announces Management Changes | CI |
| Sales 2024 * | - | Sales 2025 * | 6.12M 487M | Capitalization | 394M 31.38B |
|---|---|---|---|---|---|
| Net income 2024 * | -213M -16.96B | Net income 2025 * | -226M -17.99B | EV / Sales 2024 * | - |
| Net cash position 2024 * | 259M 20.64B | Net cash position 2025 * | 167M 13.29B | EV / Sales 2025 * | 37.1 x |
| P/E ratio 2024 * |
-2.03
x | P/E ratio 2025 * |
-2.23
x | Employees | 284 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.2% |
More Fundamentals
* Assessed data
More news
Latest transcript on Replimune Group, Inc.
More recommendations
More press releases
More news
| 1 day | +1.56% | ||
| 1 week | +1.56% | ||
| Current month | -20.20% | ||
| 1 month | -15.65% | ||
| 3 months | -19.61% | ||
| 6 months | -54.21% | ||
| Current year | -22.66% |
1 week
5.86
6.78
1 month
5.868.17
Current year
5.869.50
1 year
5.8624.81
3 years
5.8640.22
5 years
5.8654.85
10 years
5.8654.85
| Managers | Title | Age | Since |
|---|---|---|---|
Sushil Patel
CEO | Chief Executive Officer | 53 | 02/05/21 |
Colin Love
FOU | Founder | 66 | 28/02/15 |
| Founder | 52 | 28/02/15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Paolo Pucci
BRD | Director/Board Member | 63 | 31/03/20 |
Joseph Slattery
BRD | Director/Board Member | 59 | 30/09/17 |
Robert Coffin
FOU | Founder | 59 | 28/02/15 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.09% | 0 M€ | 0.00% | - | |
| 0.05% | 0 M€ | 0.00% | - | |
| 0.03% | 773 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/04/24 | 6.56 | +2.18% | 217 688 |
| 26/04/24 | 6.42 | +4.39% | 603,791 |
| 25/04/24 | 6.15 | -2.84% | 783,453 |
| 24/04/24 | 6.33 | -1.40% | 631,812 |
| 23/04/24 | 6.42 | 0.00% | 1,157,333 |
Delayed Quote Nasdaq, April 29, 2024 at 08:54 pm
More quotes
Replimune Group, Inc. is a clinical-stage biotechnology company engaged in the business of oncolytic immunotherapy to treat cancer patients. The Company is advancing a pipeline of tumor-directed oncolytic immunotherapies derived from its RPx platform to fill unmet need across cancer types. The Company's lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R and human GM-CSF. RP1 is designed to treat more immune responsive tumor types. The Company's pipeline product candidates include RP2 and RP3. The encoded GALV-GP R protein enhances the tumor killing ability of the virus and increases immunogenic cell death. RP2 is an additionally encodes an anti-CTLA-4 antibody has designed to treat more immunologically silent tumors. RP3 expresses a pair of immune costimulatory pathways activating ligands, CD40L and 4-1BBL, to further increase the potency of the immune responses to treat immunologically cold tumors.
Calendar
15/05/2024
- Q4 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
6.42
USD
Average target price
13.56
USD
Spread / Average Target
+111.15%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -22.66% | 394M | |
| +1.63% | 42.75B | |
| +47.70% | 41.61B | |
| +12.11% | 41.34B | |
| -8.83% | 26.59B | |
| +7.21% | 25.49B | |
| -23.07% | 18.12B | |
| +29.99% | 12.24B | |
| -2.27% | 11.76B | |
| +8.26% | 11B |
- Stock Market
- Equities
- REPL Stock
